In a major strategic move, the Government of Odisha has launched a comprehensive Pharma–Medical Devices Policy designed to position the state as a prominent hub for pharmaceutical and medical technology manufacturing. The policy introduces a suite of high-value incentives aimed at attracting large-scale investments into a sector that officials admit has historically had a “limited presence” in the state.

Under the new policy framework, investors will receive a 30% capital investment subsidy on plant and machinery, 100% stamp duty exemption on concessional industrial land, and a power subsidy of ₹2 per unit alongside complete reimbursement of electricity duty. The policy also provides wage incentives for five years—₹15,000 per month for women and ₹12,500 per month for men—along with ESI and EPF reimbursement, making Odisha one of India’s most competitive destinations for life-sciences manufacturing.

To streamline implementation and provide end-to-end investor facilitation, the government has established the Odisha Pharmaceutical Development Cell (OPDC). The cell will coordinate policy rollout, accelerate approvals, and shape a structured ecosystem for pharma and med-tech enterprises. The state is also progressing toward the creation of sector-specific SEZs and additional infrastructure dedicated to the life sciences industry.

The impact of these reforms is already becoming visible. According to state authorities, nine pharmaceutical and biotechnology companies have submitted investment intents worth ₹4,349 crore to set up manufacturing units, biotech plants, and healthcare facilities across Odisha. These developments align with the state’s broader Viksit Odisha 2036 vision, which aims to build a future-ready, innovation-driven industrial economy.

With investment promotion activities led by IPICOL (Industrial Promotion & Investment Corporation of Odisha Ltd.), the government has intensified outreach to industry players, highlighting streamlined processes, robust infrastructure support, and the compelling incentive package under the new policy.

To further catalyse industry engagement, the state will host the Pharma Conclave 2025 on December 16 in Bhubaneswar, bringing together policymakers, global investors, pharma leaders, and medical technology innovators. The conclave is expected to play a key role in converting investment proposals into firm commitments.

Also read: Cosmo and Glenmark Secure Market Authorisation Across 15 Countries for Winlevi® Acne Treatment 

As Odisha accelerates its transition from a limited pharma presence to a high-potential life-sciences destination, the new policy marks a pivotal step in strengthening the state’s standing as an emerging pharma-med-tech hub in India’s rapidly evolving healthcare manufacturing landscape.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!